In vitro anticancer activity of Hirudinaria manillensis methanolic extract and its validation using in silico molecular docking approach

P. Zeebul Trinita Shannan,Susan G. Suganya,E. Angel Jemima,M. Ramesh

DOI: https://doi.org/10.1007/s12032-024-02321-9

2024-03-17

Medical Oncology

Abstract:Cancer has emerged as a potentially lethal illness, which recently upsurged in the mortality rate. Animal-derived compounds could be promising targets with higher efficacy and low toxicity in anticancer therapy. The present study aimed to explore the presence of anticancer potential compounds in Hirudinaria manillensis methanolic extract and their anticancer potential against various cancer cell types and target identification by Auto dock method. Initially, the identification of bioactive compounds was achieved by GC–MS analysis followed by the anticancer activity by MTT assay against A549, HeLa, MDA-MB-231, MG-63, and MOLT-4. Further, the effect of a lead compound on the cancer cell target was analyzed by the Auto dock method. GC–MS analysis results revealed the presence of 25 different bioactive compounds including anticancer potential compounds, such as Lupeol, Carvacrol, and Demecolcine. Interestingly, MTT assay results demonstrated the anticancer potential of Hirudinaria manillensis extract (LE) against various cancer cell lines, such as A549 (54.60 μg/ml), HeLa (19.93 μg/ml), MDA-MB-231 (20.23 μg/ml), MG-63 (20.04 μg/ml), and MOLT-4 (171.8 μg/ml), respectively. Among these cell types, the maximum inhibition was observed against HeLa with the IC 50 concentration of 19.93 μg/ml. Furthermore, Demecolcine compound was docked with the EGFR tyrosine kinase showed the binding affinity of the docked complex was predicted to be − 6.2 kcal/mol. Thus, we conclude that H. manillensis has a significant anticancer effect on human cancer cell lines and could be used as a natural target which paves the way for further studies on biomedical applications in cancer therapeutics.

oncology